# FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:	3235-0287
Estimated average burden hours	per
response	0.5

OMB APPROVAL

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

 $Filed \ pursuant \ to \ Section \ 16(a) \ of \ the \ Securities \ Exchange \ Act \ of \ 1934 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Company \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Act \ of \ 1940 \ or \ Section \ 30(h) \ of \ the \ Investment \ Act \ of \ 1940 \ or \ Act \ of \ 1940 \ or \ of \ of \ 1940 \ or \ of \ 1940 \ or \ of \ 1940 \ or \ of \ 1940 \ or$ 

Instruction 10. (Print or Type Responses)

1. Name and Address of Reporting Person * Phillip Frost, M.D., ET AL			2. Issuer Name and Ticker or Trading Symbol OPKO Health, Inc. [ OPK ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) OPKO Health, Inc. 4400 Biscayne Blvd.	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/20/2025	X Director X 10% Owner X Officer (give title below) Other (specify below) CEO & Chairman			
Miami, FL 33137	(Street)		4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person			
(City)	(State)	(Zip)					

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	2A. Deemed Execution Date, if any (Month/Day /Year)	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership
			Code	V	Amount	(A) or (D)	Price			(Instr. 4)
Common Stock	11/20/2025		P		119,129	A	\$ 1.32	215,665,577	I	See Footnote
Common Stock	11/20/2025		Р		47,105	A	\$ 1.325	215,712,682	I	See Footnote
Common Stock	11/20/2025		Р		211,948	A	\$ 1.33	215,924,630	I	See Footnote
Common Stock	11/20/2025		P		161,818	A	\$ 1.335	216,086,448	I	See Footnote
Common Stock	11/20/2025		P		24,579	A	\$ 1.34	216,111,027	I	See Footnote
Common Stock	11/20/2025		Р		1,757	A	\$ 1.345	216,112,784	I	See Footnote
Common Stock	11/20/2025		Р		13,664	A	\$ 1.35	216,126,448	I	See Footnote
Common Stock								3,568,951	D	

Common Stock	ĺ		I		30,127,177	I	See
							Footnote
							(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	or Exercise	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	of C Derivative F	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported	or Indirect (I) (Instr. 4)	

	and Address of Reporting Person* Frost, M.D., ET AL	,	
(Last)	(First) Health, Inc. scayne Blvd.		(Middle)
(Street) Miami	FL		33137
(City)	(State)		(Zip)
Relationsh	nip of Reporting Person(s) to Issue	er	
X X	Director Officer (give title below) CEO & Chairman	X	10% Owner Other (specify below)
	and Address of Reporting Person*  Trust	,	
	(First) Health, Inc. scayne Blvd.		(Middle)
(Street) Miami	FL		33137
(City)	(State)		(Zip)
Relationsh	nip of Reporting Person(s) to Issue	er	
	Director Officer (give title below)	X	10% Owner Other (specify below)

# **Explanation of Responses:**

- 1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 2. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Phillip Frost, M.D., Individually and as Trustee	11/20/2025
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## JOINT FILER INFORMATION

Name: Frost Gamma Investments Trust

Address:

4400 Biscayne Blvd. Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: November 20, 2025

Relationship to Issuer: 10% Owner

## FROST GAMMA INVESTMENTS TRUST

By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee